title: Psychomotor slowing, neuroendocrine responses, and behavioral changes after oral administration of meta-chlorophenylpiperazine in normal volunteers.
abstract: The mixed 5-HT receptor agonist/antagonist meta-chlorophenylpiperazine (mCPP) is known to suppress locomotor activity in mice and rats. This study aimed: (1) to determine whether mCPP induces cognitive and motor changes in normal human volunteers and how these changes relate to the neuroendocrine effects of mCPP; and (2) to compare these cognitive and motor changes to the known cognitive and motor slowing patterns in depression and schizophrenia. A computerized method (used in previous research) analyzed fine motor behavior during figure-copying tasks. In 14 normal male volunteers behavioral responses, body temperature, plasma levels of prolactin and cortisol, and cognitive and motor performance during figure-copying tasks were measured after a single oral dose of mCPP (0.5 mg/kg). mCPP-induced prolongation of the reaction times in all copying tasks, parallel to increases in cortisol and prolactin and some self-reported behavioral effects. There were no changes in the movement times or the velocities of the writing movements. In conclusion, mCPP induced cognitive, but not motor slowing, in normal male volunteers. This indicates that the human serotonin system is also implicated in psychomotor behavior. This pattern of slowing was different from that in depressed and schizophrenic patients.
authors.affiliation: Department of Psychiatry, University of Nijmegen, Reinier Postlaan 10, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. b.sabbe@czzopsy.azn.nl
authors.forename: B
authors.initials: B
authors.lastname: Sabbe
authors.forename: W
authors.initials: W
authors.lastname: Hulstijn
authors.forename: M
authors.initials: M
authors.lastname: Maes
authors.forename: M
authors.initials: M
authors.lastname: Pier
authors.forename: S
authors.initials: S
authors.lastname: Scharpé
authors.forename: F
authors.initials: F
authors.lastname: Zitman
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001831:Body Temperature / Q000187:drug effects; D003072:Cognition Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000378:metabolism*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011388:Prolactin / Q000097:blood*; D011596:Psychomotor Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000378:metabolism*; D011930:Reaction Time; D011985:Receptors, Serotonin / Q000378:metabolism; D012559:Schizophrenia / Q000378:metabolism
chemical_list: D010879:Piperazines; D011985:Receptors, Serotonin; D011388:Prolactin; D006854:Hydrocortisone